Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Exclusives

More »

For full access to this article login to GEN Select now.

Jun 12, 2014

Bioprocessing Trends to Expect in 2014

BioPlan Associates presents the results of its latest annual survey.

Bioprocessing Trends to Expect in 2014

For its 11th annual survey, BioPlan received responses from 238 global biomanufacturers in 30 countries, and 158 suppliers to the industry. [© Andrei Merkulov - Fotolia.com]

  • The biopharmaceutical industry is in good health, with total annual sales now approaching $200 billion and growing at ~15% annually—as it has over the ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.
    •  


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »